INmune Bio stock soars after prostate cancer trial meets endpoints Investing.com -- INmune Bio Inc. (NASDAQ:INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both primary and secondary endpoints and is now closed to enrollment. The clinical-stage immunology and inflammation company reported that INKmune™ demonstrated an excellent safety profile at all three dose levels tested in the "CaRe PC" trial, achieving the primary endpoint. Additionally, patients with low natural killer (NK) cell activation showed the greatest improvement in biomarkers of NK cell activation, helping define the target population for future trials. "INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease," said Dr. Mark Lowdell, CSO at INmune Bio. "Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing." Following these positive results, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease. This approach aims to enable more robust measurement of the drug’s effects and potential clinical benefits. The company’s shares responded strongly to the announcement as investors appeared to welcome the positive trial results and advancement of the INKmune™ program. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #INMuneBio #ProstateCancer #StockMarket #InvestmentNews #ClinicalTrials

Exciting topline results from a #Phase2 trial in #Alz presented at #AAIC25 by #INmuneBio showing #solTNFinhibition by #XPro1595 in amyloid positive patients with 2+ biomarkers of inflammation in blood slowed cognitive decline in a 6 mo trial 🤓💪🏼💜🧠

INmune Bio slumps on midstage fail for Alzheimer's drug INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.

Shares in #INmuneBio lost almost two-thirds of their value in premarket trading this morning as it emerged that its drug candidate for #Alzheimersdisease flunked a highly anticipated phase 2 trial.

pharmaphorum.com/news/inmune-...

PRISM Mid-Day Movers: Robotic Medical Innovation and Disappointing Earnings Diverge Indices
#NanoVibronix Inc. ( #NAOV)
#AethlonMedical Inc. ( #AEMD)
#INmuneBio, Inc. ( #INMB)
#HeliusMedicalTechnologies, Inc. ( #HSDT)
#AdialPharmaceuticals, Inc. ( #ADIL)

prismmarketview.com/prism-mid-da...